Table 1 ALTTO Cardiac population.

From: Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

Characteristic

T arm (2097 patients) N (%)

T + L arm (2093 patients) N (%)

p-value

Age (years)

  

0.918

 <65

1881 (90)

1879 (90)

 

 ≥65

216 (10)

214 (10)

 

Baseline LVEF

  

0.765

 50–54%

98 (5)

102 (5)

 

 55–64%

1065 (51)

1053 (50)

 

 >64%

934 (44)

937 (45)

 

 Missing

0

1 (<1)

 

LVEF evaluation method

  

0.616

 ECHO

1588 (76)

1571 (75)

 

 MUGA scan

509 (24)

522 (25)

 

Any co-morbidity?

  

0.470

 Yes

588 (28)

566 (27)

 

 No

1509 (72)

1527 (73)

 

BMI (kg/m2)

  

0.916

 <25

999 (48)

989 (47)

 

 25–30

679 (32)

675 (32)

 

 >30

419 (20)

429 (21)

 

Hypertension

  

0.293

 Yes

471 (22)

442 (21)

 

 No

1626 (78)

1651 (79)

 

Diabetes Mellitus

  

0.024

 Yes

128 (6)

95 (5)

 

 No

1969 (94)

1998 (95)

 

Hypercholesterolemia

  

0.290

 Yes

179 (9)

160 (8)

 

 No

1918 (91)

1933 (92)

 

Radiotherapy lateralitya

  

0.165

 Left

745 (50)

790 (53)

 

 Right

736 (50)

698 (47)

 

 Bilateral

5 (<1)

2 (<1)

 

Chemotherapy regimen

  

0.902

 Anthracycline followed by taxane

1985 (95)

1983 (95)

 

 Non-Anthracycline (docetaxel + carboplatin)

112 (5)

110 (5)

 

Median doxorubicin cumulative dose

237.62 mg/m2

237.84 mg/m2

–

Median epirubicin cumulative dose

350.86 mg/m2

349.75 mg/m2

–

Median follow-up (IQR) in years

6.9 (6.0–7.1)

6.9 (6.0–7.1)

–

  1. BMI body mass index, ECHO echocardiogram, LVEF left ventricular ejection fraction, IQR interquartile range, MUGA multiple-gated acquisition, T trastuzumab, T + L trastuzumab + lapatinib.
  2. aPercentages derived using 1486 patients on T arm and 1490 patients on T + L arm that received radiotherapy as denominator.
Back to article page